Introduction: A number of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have been evaluated in cardiovascular outcome trials (CVOTs). In this study, we aim to examine the generalizability of results from GLP-1 RAs CVOTs among Chinese type 2 diabetes (T2D) population.
Methods: Patients enrolled or eligible for inclusion in four GLP-1RAs CVOTs (EXSCEL, LEADER, REWIND and SUSTAIN-6) were examined in reference to 3B (Blood Glucose, Blood Pressure and Blood Lipid) population, a nationally representative population of T2D patients in China (n=25,411). We descriptively compared key baseline characteristics of the populations in each trial to those in 3B population. We also estimated the proportions of patients in 3B population who would have met the six key inclusion and exclusion (I/E) criteria (age, HbA1c, BMI, eGFR, CVD history and antidiabetic medication) in each trial.
Results: The REWIND population most closely matched 3B population in sex, diabetes duration, HbA1c, DBP, LDL, CVD history and prior MI. The EXSCEL most matched in age, BMI and SBP, while the SUSTAIN-6 most matched in eGFR (Table 1). Based on I/E criteria, 31.10% of the 3B population were eligible for enrolment in REWIND, versus 15.04% in SUSTAIN-6, 12.97% in LEADER, and 11.30% in EXSCEL.
Conclusions: Among the four CVOTs, REWIND has the most generalizable eligibility to the Chinese T2D population.
X. Cai: None. L. Zhang: Employee; Self; Eli Lilly and Company. H. Wu: None. L. Huo: Employee; Self; Eli Lilly and Company. X. Ma: None. H. Cao: None. L. Ji: None.
